Circulation Subspecialty Journal's Editors-in-Chief June 2019

Dr Amit
Khera:                 
Welcome to Circulation On The Run. Our weekly podcast summary and
backstage pass to the Journal. I'm Dr Amit Khera, associate
editor and digital strategies editor from UT Southwestern Medical
Center in Dallas, and I had the distinct privilege of standing in
for Dr Carolyn Lam and Greg Hundley this week. Twice a year, we
are very fortunate to have some unique podcasts when we don't
have circulation issues, and in the past we've met with many
fellows in training and heard about some interesting studies that
they're doing. Today we have a very special podcast we have not
done before, and that is one where we had the opportunity to
learn about our Circulation Family of Journals, and more
importantly to hear from the dynamic editors in chief of these
various journals. I think you're really going to enjoy it, we'll
walk through and hear from each one of them, hear about some of
the innovative things that are happening, some of the future that
they see for their journal in their field, and I really enjoyed
it, and I'm sure you will as well. So, without further ado, we'll
start with our first editor.


Dr Sunil
Rao:                     
I'm Sunil Rao. I'm an intervention cardiologist at Duke, and I'm
the Editor-in-Chief for Circulation Cardiovascular Interventions,
which is one of the daughter journals of the Circulation Family.
We publish articles really related to the broad spectrum of
interventional cardiology, from coronary interventions to
peripheral arterial disease, and Endovascular interventions to
structural heart disease interventions. We also published review
articles in all of those areas, as well as any health policy or
outcomes studies that are in that space.


Dr Amit
Khera:                 
Tell us what are some of the innovative things that your journal
is doing this year.


Dr Sunil
Rao:                     
We're really excited about two things, one is our extremely
successful Assistant Editor program that we launched last year at
A.H.A. 2018. This is a program where we have five early career
individuals that are within five years of completing their
fellowship program who joined the editorial team at Circulation
Cardiovascular interventions, and in that role they really learn
a lot about the mechanics of how scientific publishing works,
they commit to doing manuscript reviews, and receive feedback on
improving their peer review process, and even independently
handles some manuscripts as well, that are in their areas of
interest. This is our way, I think, of encouraging the next
generation to stay engaged with science, and with the scientific
publishing process. It's been extremely successful. Assistant
editors are part of our team for a two year term. So, in 2020, we
will be selecting the next class of assistant editors, and after
their term is ended, they join our editorial board as editorial
board members. So, we're really excited about that, it's been an
overall positive experience, for I think everybody involved. The
second thing that we're really excited about is that we launched
a social media presence for the journal, which it previously did
not have. So, we have a very active Circulation Cardiovascular
Interventions Twitter handle, I encourage all the listeners to
join Twitter if you're not on Twitter, and if you are on Twitter
please follow at Cirque intervened. It's " at C.I.R.C.I.N.T.V.".
That is the official Twitter handle for our journal. Dave Fishman
is our social media editor, and Chadi Alraies is our assistant
social media editor, and we're not just tweeting out the
articles, and providing summaries when the papers get published,
we're holding Twitter journal clubs once a month ,and these have
been extremely successful, it's an hour long Twitter journal club
where the discussion gets very intense, and there's a lot of back
and forth. We try to have the authors on as well, so that they
can explain the rationale for their study, some of the challenges
that they face when they are doing the study, and hopefully
provide some implications for clinical practice, and what the
next steps are. That's a way for us to engage our readership,
it's almost a form of post publication peer review, which I think
is becoming very popular. In addition, remember we don't have a
print format of our journals, so this is a way to get the
readership more engaged with the Web site, and to come to our
website and learn what elsewhere publishing, and how they can get
involve with the Journal as well, both as authors who submit
their work, or if they want a peer review for us, please contact
us and let us know.


Dr Amit
Khera:                 
I really love hearing about the Twitter journal club, I know that
they are well received, and certainly getting a lot of traction.
Tell us about what initiatives or topics you're most excited
about this year, and maybe some things that are coming later in
the year.


Dr Sunil
Rao:                     
We're really excited about the big areas in interventional
cardiology, which are coronary physiology, we've published quite
a few papers on looking at different physiological parameters,
and how they can drive the appropriate use of PCI and how that
affects outcomes. I think that's going to continue to be a huge
topic over the next year, Certainly such a heart disease has
exploded, and with the data on low risk patients undergoing TAVR,
and having really good outcomes, we're seeing a lot more
submissions in the low risk TAVR space, the other area that's
really exploding right now is Mitral and Tricuspid Valve
Interventions, one of the areas that I think has seen a
tremendous amount of device innovation. So, we're seeing a lot of
submissions from really high quality papers in that space, but I
think it's also important to note, that unlike previous
iterations of the Journal, we're actually having a review
article, we're trying to have a review article every month on a
major area that is burgeoning, so that the readership can
understand the overall lay of the land, with respect to evidence,
how that guy's clinical practice, and what's coming next. So,
we've published quite a few review articles already, and there
are more to come, and I think that's a really important way for
the readership to keep current with what's going on in
Interventional Cardiology.


Dr Amit
Khera:                 
What about the advancing aspects of your subspecialty? There's so
much going on in interventional cardiology, it's a bit dizzying,
just tell us a little bit about some of the ways that your
journal's helping advance that mission, not just now but perhaps
in the future.


Dr Sunil
Rao:                     
I think one of the challenges that we have at Interventional
Cardiology, and maybe this is true across Cardiology, is that the
evidence is developed very rapidly, and oftentimes it almost
seems like the field is lurching back and forth in certain areas,
a prime example of that is the drug coated balloon controversy
for Peripheral Interventions. The Journal Of The American Heart
Association published a meta-analysis, showing that there may be
an association between the use of these devices and increased
mortality, that has led to a lot of discussion in the
interventional community, and quite frankly I think there's a
fair amount of confusion out there about whether we should be
using these devices, should we put a moratorium on these devices,
is the signal real, if it is, what's the mechanism of death. So,
a lot of conversation around that, in fact, it's led to what's
going to be a focused FDA meeting in June, specifically on the
drug coated balloon controversy. Where I see our journal playing
a role is really in trying to, not only publish the latest
science, which is rigorous in the field for controversial topics
such as this, but also to help provide some context for that
science, and I think our integrated strategy of original science
review articles, and social media really helps us to communicate
with the readership, and with the Interventional Cardiology
community writ large, meaning not just physicians, but also Cath
lab staff, nurses, noninvasive cardiologists who obviously have
patients who are undergoing interventions, and even policymakers,
to keep them abreast of what's going on, so that they can have
the same level or base of knowledge, so that the conversation is
on a level playing field.


Dr Amit
Khera:                 
Okay, well you heard it from Dr Sunil Rao. Thank you for your
time.


Dr Kiran Musunuru:        I'm
Kiran Musunuru, I'm the outgoing Editor-in-Chief of Circulation
Genomic and Precision Medicine. Let me start by saying a little
bit about the content of the journal, it considers all types of
articles related to, as the name implies, Genomic and Precision
Medicine, and more specifically, Clinical Genetics, the molecular
basis of complex cardiovascular disorders, considered at a
variety of levels, that can include a lot of different, what we
would call Omics Techniques, from Genomics to Transcriptomics,
Proteomics, Metabolomics, Metagenomics, and, so forth. It also
deals with big data applications, that includes Electronic Health
Record Data, Patient generated data combined with any of the
things I've already mentioned, Genome Wide Association Studies,
Pharmacogenomics, Gene Therapy, Therapeutic Gene Editing, Systems
Biology. So, it's a pretty comprehensive look at all the various
topics that would fall under the rubric of Genomic and Precision
Medicine.


Dr Amit
Khera:                 
Now, Dr Musunuru, you mentioned the outgoing Editor-in-Chief,
let's introduce the incoming Editor-in-Chief, Thatcher
Christopherson Semsarian.


Dr Chris
Semsarian:         I'm
the incoming Editor-in-Chief. My name is Chris Semsarian, I'm a
cardiologist at the Royal Prince Alfred Hospital in Sydney,
Australia.


Dr Amit
Khera:                 
What are some of the innovations you and the Journal are doing
this year, or, what are some of the things you see coming in the
future?


Dr Kiran Musunuru:       
Something I'm very excited about, is that we are just starting a
pilot project with the American Heart Association's Institute for
Precision Cardiovascular Medicine. The institute has a very nice
platform called the Precision Medicine platform, and, in
brainstorming last year, we realized there was a very nice
opportunity to try to create a new type of journal article.
There's also a big move in science nowadays to improve
transparency, and rigor, and reproducibility, especially in
science. The idea being that ideally other investigators should
be able to take one team's work, and be able to run through the
entire analytical process, and reproduce the original findings,
and perhaps even find ways to improve upon those original
findings, and, so we realized working with the institute's
Precision Medicine Platform, we had the opportunity to actually
make a new type of article, we think of, as the paper of
tomorrow, a virtual article. The idea would be, that we would
have primary data on the Precision Medicine Platform, the
analytical tools used to process the data would also be on the
Precision Medicine Platform, the analytical plan, in the form of
a so-called Jupiter notebook, that basically takes people step by
step through exactly which tools were used in which order, in
which way, with which parameters, would be on the Precision
Medicine Platform, and then there would be some verbal
explanation, some background, to explain the context of these
analysis, and to really put it into perspective, as how it fits
into the body of literature, and so the idea would be, this would
live on the Precision Map Platform in a virtual format, and then
anyone else who is interested in this work could come, and
actually directly interact with the data, and the tools, and the
analytical plan, and could actually rerun the entire papers work
from scratch, thus reproducing it, and then could actually tweak
the analytical plan, or install tools of their own, and be able
to build upon the work that had already been done. It's a very
different way of thinking about journal articles, more as living
entities rather than static work that just lives on a page, and
is there as reported, and then never has an opportunity to be
fully produced or improved upon.


Dr Amit
Khera:                 
There's so much happening in the space of genomics, and
obviously, we hear the word "Precision Medicine" so commonly.
Tell us a bit about how your journal in specific is advancing the
mission of your area.


Dr Kiran Musunuru:        I'll
say a little bit, and then maybe turn it over to Chris, give his
perspective as the incoming Editor-in-Chief. I think it's a
vibrant field, but it's also a very new field, it's evolving
rapidly, and I think the Journal has a very important role to
play, and not only reporting the results that are coming out of
studies in this field, but actually having a role to play in
helping to shape the field, helping to define the field, it's
very exciting, it's very much in rapid evolution. Just ten years
ago or so, when the Journal first started, we were just starting
to see the first Genome Wide Association studies, and now we've
gone so far beyond that.


                                               
Now, again, we're talking about these large bio banks, we're
talking about Precision Medicine, we're talking about applying
this information in health care, we're talking about combining
all of these various streams of data and many levels to be able
to do studies, that are, I would even say, exponentially advanced
beyond what we able to do just ten years ago, and so, it's very
exciting times for the journal, then maybe I can ask Chris to
share his thoughts on that.


Dr Chris
Semsarian:         Yeah
Kiran, I mean, it's a great honor system to follow in your
amazing footsteps, and what you've done for the Journal, and as
the incoming Editor-in-Chief, I really want to sort of try, and
build on the platform that you've established over the last few
years, and really, one of the areas that I'm particularly
interested in is the area of Translation of Genomic Findings. I
mean, ultimately what we do in our lives, as clinicians, is to
help patients improve diagnosis, to improve the treatment of
these patients, and to be able to do studies with very basic
understanding of how our genomes work, and how Narcotic Genes
interact, and translating those findings into these improved
diagnostic approaches, and even in guiding management is really
exciting, I think, in terms of clinical medicine, and improving
patient care as we look ahead. I really want to be able to
continue to publish really, state of the art, novel, innovative,
research areas, that you've already covered, Kiran, which would
lead to better care of our patients, who are ultimately the
beneficiaries of this type of amazing work.


                                               
So, I'm really excited looking at the Journal, it's a tremendous
area of interest and research, where there's twenty-two thousand
genes approximately now genomes, and we really don't understand
most of them in terms of their intricate function, and I figured
it's a great time ahead, in terms of Precision Medicine.


Dr Amit
Khera:                 
Okay, well, that was Dr Kiran Musunuru, and Christopher
Semsarian, we appreciate both of your time today for Circulation
on the Run.


Dr Paul
Wang:                  
I'm Dr Paul Wang, I'm the Editor-in-Chief of Circulation
Arrhythmia and Electrophysiology. Our Journal covers really the
expanse of our field, going from basic mechanisms of arrhythmias,
so very basic science work, to really clinical practice, clinical
outcomes, to population based studies, and genetic based
considerations in our field. So, we really feel we encompass the
entire range, and there really isn't any topic within our area,
that we don't feel is outside our realm.


Dr Amit
Khera:                 
I know there's so many innovative things you're doing, Dr Wang,
with your journal. Why don't you tell us a little bit about your
plans for this year.


Dr Paul
Wang:                  
We've been excited; our team has been at the Journal for two
years now, and we focused on a number of different areas. So, I
think one of our biggest advances, and we've tried to be more
responsive to the authors, so we've really reduced the time to
first decision very substantially, from over twenty days, to ten
days or less, I think we hit a record of 7.8 days in the journal.
So, really, we hope we're more responsive, we've involved the
editorial board, we've substantially expanded it, so that more of
our reviews of greater proportion going to our editorial board,
which is a really fabulous, internationally recognized group,
with really high quality reviews, so we've been very pleased,
with both a level of science that we've received, as well as the
level of the reviews that we have. One other area is, we really
want to make sure that the reviewers, who do much of the heavy
lifting, in addition to our editors for The Journal, and so we've
established a new Reviewer Recognition Award System, they can be
designated as silver, gold or platinum, and we've reached out to
department chairs, or their deans, and recognizing that they won
this prestigious award for their performance, and great work with
the Journal, so there are a number of different things that, in
fact, we think we've made some advances in, the other areas are
really that of extending our reach, and so, one of the things we
concentrated on, initially with the adding of podcasts, so we do
that monthly.


                                               
All the articles are now available in review, and then what we're
starting at our new initiatives is, we'll be starting a Twitter
Journal Club. I've been recording at least two of our articles,
as the interview with the authors, and then we're going to be
having a journal club, in which we will have the opportunity for
people around the world to comment, and have a discussion that
will really be exciting, we think. So, there are a number of
other areas that we're thinking about, in terms of that kind of
work.


Dr Amit
Khera:                 
The field of Electrophysiology seems to be changing by the day,
maybe you can tell us a little bit, about how the journal is
advancing the mission of the field of electrophysiology.


Dr Paul
Wang:                  
So, one of the things that we focused on is the role the Journal
can play, in terms of connecting with other elements of our
field, and one of the ways that we've really concentrated on is,
in particular, working closely with the American Heart
Association, and its committees. We're related to a number of
committees, but particularly, there is a committee on
Electrocardiography, Electrophysiology, part of the Clinical
Cardiology Council, and so, we work very closely with that group,
and, in fact, we've invited that group to create proposals for a
number of review articles, state-of-the-art reviews, that we hope
will come out in the next year or so. The ways in which we can
tie together our committees to AHA overall, I think, is really
the direction we're looking for our journal, and we feel we can
play a very novel, and innovative role in that regard. We, for
example, also reached out to the American Heart Association
funded researchers in our area, and invited them to participate
in the journal, participate in our committees, become fellows or
FAHA's of the American Heart Association, so we really want to
create this family, a real community, and sense of community,
that we hope will stem from the Journal. So, we're very excited
about the future, and what we might be able to achieve together.


Dr Amit
Khera:                 
Thank you so much, Dr Paul Wang for your time today, and we
appreciate your insights on Circulation, Arrhythmia and
Electrophysiology.


Dr Nancy
Sweitzer:         
Hi, I'm Nancy Sweitzer. I'm the Editor-in-Chief of the Journal
Circulation Heart Failure. At Circ Heart Failure, we deal with
all things related to heart failure. Heart failure is an
expanding specialty, relatively new subspecialty in cardiology,
and we're very interested in the physiology, and mechanisms of
heart failure, as well as treatments of heart failure, and the
innovative evolution of the specialty which includes Advanced
Hemodynamics, Mechanical Circulatory Support, and transplant as
therapies, as well as all Implanted Device Therapies, and new,
and Innovative Pharmacologic, and Gene Therapies as well.


Dr Amit
Khera:                 
Tell us a bit about initiatives, or features in Circulation Heart
Failure, that you're planning on tackling not only this year, but
into the future.


Dr Nancy
Sweitzer:         
The effort we're most excited about at Circulation Heart Failure
has been ongoing now for a little over a year, but continues, and
is really focused on the emerging scientists in the Heart Failure
Space; we call it our "Featured Emerging Investigator Spotlight",
and this spotlight focuses on authors of manuscripts, who are
within ten years of their terminal training, and can take full
responsibility for the content of a manuscript. When we publish a
featured emerging investigator article, which we've done more
than half of the months since launching the feature in late 2017,
we schedule a Twitter Journal Club with that author, where we
participate, over the course of several hours, in pretty
intensive conversation, about not only the science, but career
development in Heart Failure Space, the importance of mentoring,
and sponsorship obstacles that people are facing in development
as physician scientists or scientists, and insights they may have
into fostering success in the Heart Failure Space. This has been
a great feature, we launched it because we feel that the emerging
scientists, in the Heart Failure Space, need a virtual community
in those critical years, before you have a lot of resources to
start traveling, and setting up a network that's based on
personal interaction, and we felt that, the modern era of social
media was perfect for this. We found our emerging investigators
are getting to know one another, they participate in one
another's Journal Clubs, the Journal Clubs are incredibly fun,
and interactive and we're getting a lot of Twitter engagement
from the Heart Failure Community, there's a lot of "Twitteratti"
in Heart Failure that really are engaged, and engaged with the
Journal, which has really been fun for all of us, I think, so
that's the thing we're most excited about.


Dr Amit
Khera:                 
It's really wonderful to hear how you're spotlighting authors in
creative ways. Tell us a bit about how your journal is advancing
the mission of Heart Failure and Transplantation.


Dr Nancy
Sweitzer:          I
see the journal as central to advancement of the subspecialty, as
I mentioned earlier, Heart Failure is a relatively young
subspecialty in the United States, we received a CGMC designation
as a subspecialty just in 2008, just eleven years ago, and it's
been a board certifiable subspecialty only since 2014. So, we're
very young, and I think really developing into our own. We've
seen tremendous growth in the number of people seeking
subspecialty training in Advanced Heart Failure and Transplant
Cardiology, and we are really enjoying helping the Journal evolve
with the specialty, as it evolves, and that's happening very
actively right now. So, I think what Heart Failure is in 2019 is
different than what it was just five years ago in 2014. We're
doing a lot more ,as I mentioned, Complex Chemo Dynamic Thinking,
thinking about the path of physiology in our patients, and how we
can target that effectively, not only with existing therapies,
but with strategies, and, as I mentioned, the burgeoning growth
of Mechanical Circulatory Support, and support devices, which the
field has embraced quite actively, and The Journal is
increasingly publishing content in these spaces, as well as the
spaces of Advanced Heart Failure, but, I guess also, we're
interested in every aspect of Heart Failure, from Complex
Multidisciplinary Care Management, to Palliative Care, to the
interaction of the heart with other organ systems, and Heart
Failure such as the brain, we have a paper on Cognitive Function
Abnormalities, and Heart Failure in this month's issue. So, the
interaction with the brain, the kidney, the liver, many other
organs, that are affected when the heart becomes quite ill with
Advanced Heart Disease. So, basically we're interested in
everything that touches Heart Failure Development Care, and
treatment of patients with Heart Failure, and particularly we're
interested in the newest and latest. We love publishing, and some
of our highest impact papers in the last couple years have been
new therapies, just being tested for the first time in patients
with heart failure. Small studies that may not have large impact
in terms of heart outcomes, but where we're learning about the
pathophysiology of the disease, and new treatments, that's really
exciting to us. We've published a couple of methods papers in the
last year, really innovative models. One describing a model of
pacing in mice, which has been a really challenging thing to do
in Heart Failure, but several groups have now developed
Tachycardia induced Cardiomyopathy models in mice, which is
important for rapid discovery work, because mice have such a
short reproductive span, and can be genetically altered, and then
a recent publication on the methods paper, looking at a new
initiative by the FDA, to potentially approve therapies based on
patient reported outcomes, rather than just heart mortality and
morbidity outcomes, so we're really excited about the
innovations, and the Heart Failure Space, the work that describes
where we're going as a field and as a profession. You'll see some
features coming up in the journal, from opinion leaders across
the globe on where this specialty sits in 2019, and where we, as
the leaders in the field, can guide it as we move into our next
decade, and I think that some of the most exciting work the
journals doing.


Dr Amit
Khera:                 
Thank you, Dr Sweitzer. We really appreciate your time today for
the podcast, and your insights on the Journal.


Dr Robert
Gropler:         
Good afternoon, I'm Rob Gropler. I'm the Editor-in-Chief of
Circulation Cardiovascular Imaging. It's one of the journals
within the family of Circulation Journals, and our focus is
really on being the most influential source of leading edge
imaging sciences, as it relates to transforming cardiovascular
care, so what that means is, that we're interested in all imaging
studies that are applied to the care of the cardiovascular
patient, and although our primary focus is really on clinicians,
and researchers, but we also want to expand our viewership, if
you will, to anyone who is interested in how imaging is used to
understand Cardiovascular Medicine, and to treat patients with
Cardiovascular Disease. So, we are edged in all forms of imaging,
this can be from MR, to echo, to nuclear, to CPT, to optical
imaging, it involves all types of disease, ranging from
Congenital Heart Disease, up to diseases in the elderly, it also
involves not just it is in humans, but also understanding disease
in the preclinical space, particularly as it helps us understand
new technologies that may ultimately reach human use, either for
investigational purposes, or ultimately, to be used in the
treatment of a patient with Cardiovascular Disease.


Dr Amit
Khera:                 
What are some innovative things you and the Journal are planning
for this year?


Dr Robert
Gropler:         
We're doing quite a few things. One of the first things we did,
as you know, were relatively new, where we've only been an
editorial team, if you will, for one year. One of the major
efforts has been to increase our presence, in terms of digital
media strategies, across the board. And so, this meant expand our
Twitter presence, if you will. It also meant increasing our
offerings in that digital space by, for example, having a journal
club, what we would do is on a every other month basis, discuss a
paper we published that's of significant interest via Twitter.
And it would involve the authors, the associate editors who
actually manage that study, as well as the editorialist who wrote
about that study, and it leads to very unique insights into how
that paper is being viewed by the scientific community at large,
and also potentially how that information will be implemented in
terms of transforming clinical care.


                                               
We've added what we call a teaching file. If you think about
imagers, imagers learn by seeing images. And the more they can
see images, put them in the context of clinical cases, the more
they understand what an image means when they see it. So, what we
do now is we accept a large number of what we call imaging cases.
These are specific unique cases that have a history, and then a
short write up about them.


                                               
And those are gathered each month, but then they're downloaded
into a file. And then, anyone with access to the Journal can then
look at, use to learn from, to potentially use for talks to
enhance their own education the education of others. And we have
found that to be, again, another offering that our readers
particularly like.


Dr Amit
Khera:                 
And how do you see Circulation Cardiovascular Imaging advancing
the mission of imaging, which seems to be ever-expanding, and
ever-growing?


Dr Robert
Gropler:         
We're really in the education business. And what that means is
that we're educating at a multi-scale level. Just educating a
practitioner on what technology can do, how it's helping
cardiovascular medicine, yes, that's important. But what we're
also doing, is we're educating the scientists as to here as some
of the new findings that were coming out because of imaging. And
then that, in turn, will help direct them or signal them as to
where is the science leading them, and what should be their next
steps?


                                               
We're also educating the general public as to what can imaging
do, and how does imaging change cardiovascular medicine for the
better, and what they can expect from that. And we're also
educating the regulatory bodies, if you will, that determine what
imaging can be done in the clinical environment and so on, and
the importance of these imaging techniques.


                                               
So number one, I think we always have to maintain that focus, as
to that's our goal. Now, that being said, I think the question
becomes how do you convey that concept? And where we have to
continually evolve.


                                               
And I think they were very smart years ago to make it a
digital-only journal, as opposed to combined print and digital.
So, I think that was actually very savvy. But the digital net
component now has to expand. And that means our offerings have to
reflect not just that people learn in different ways, that is, we
have to have not just, if you will, a didactic or print
equivalent component of a paper. But it also should be
audio-based, such as this podcast. But they also need to be
varied as in terms of the types of offerings, and their brevity
or length, if you will.


Dr Amit
Khera:                 
Thank you, Dr Robert Gropler, the Editor-in-Chief of Circulation
Imaging. We really appreciate your time today.


Dr Robert
Gropler:         
Thank you very much. You have a great day.


Dr Amit
Khera:                 
Well, I'm sure you enjoyed this as I did. We really got
incredible insight from the Editors-in-Chief of our Circulation
family of journals. We learned so much about the broad array of
subspecialties that they cover, and all the exciting and
innovative things they're doing to really advance the missions of
their fields, and also for the authors and for science.


                                               
Well, again, I'm Amit Khera, associate editor from UT
Southwestern, Digital Strategies editor for Circulation. And next
week, you'll have your usual hosts, Carolyn Lam and Greg Hundley.


Dr Carolyn
Lam:               
This program is copyright American Heart Association 2019.